24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
It brought together experts, regulators and all participants in the pharmaceutical industry market and demonstrated impressive results. 20 events of the business program were attended by 1313 specialists, which is 22% higher than last year. This confirms the relevance and acuteness of the topics discussed, the high level of experts and the desire of market participants to gain new knowledge, exchange experience and find solutions for their production problems. Within the framework of the program, key issues of import substitution, localization, digitalization, GMP standards, biotechnology, quality control and testing were considered.
The business program of the exhibition opened with the discussion session "ColdChain: Pharma Logistics". The moderators of the first event of the Pharmtech & Ingredients 2025 business program were Natalia Stepanova, CCTT Deputy Secretary General, and Mikhail Sinev, President of the Association of Food Sector Organizations (ASORPS). Tadzio Schilling, CEO of the Association of European Businesses (AEB), outlined a number of issues common to foreign manufacturers that affect the supply chain: regulatory challenges, the complexity of implementing and obtaining the status of an authorized economic operator, licensing requirements for the handling of medicines. Yulia Lygina, Head of the Department for the Transportation of Narcotic Drugs, Museum Exhibits, Art and Cultural Values of the FSUE CCCC, noted that in the past few years, in addition to such violations of ColdChain as theft or non-compliance with the temperature regime, we have to talk about a new risk - the risk of sabotage and substitution. According to the expert, over the past year, there have been shifts in the discussion of legislative initiatives in the field of transport safety, but there are competencies that are available only to state-owned companies. Anna Filippova, Director of Pharmaceutical Sector Development at WELLGO, called air transportation multimodal delivery, where there are always risks of transshipment, and the least controlled stage is cargo handling under the aircraft, when a temperature violation is possible. Road transportation by direct car, according to the speaker, is the most reliable solution for the delivery of large consignments of temperature-controlled cargo, and container, sea and rail transportation has great potential in the future. Partners: CCTT, ASORPS
 |  |
On the first day of the exhibition, a round table "From import substitution to technological leadership. New challenges for the Russian veterinary pharma". Timur Chibilyaev, Executive Director of the Association for the Promotion of the Development of Veterinary Business "National Veterinary Association", presented a report on the production of veterinary drugs. Nikolay Bespalov, Development Director of RNC Pharma, spoke about the volume and dynamics of the retail market of veterinary drugs and noted the impressive growth rates. Vasilina Gritsyuk, Deputy Director of VGNKI, noted that over the past 4-5 years, Russian veterinary pharma has shown stable growth. If earlier attention was paid mainly to antibacterial agents, now the following are developing: anti-inflammatory, hormonal, detoxifying, sedatives, diuretics, antiemetics. According to the expert, today Russian companies are not just replacing foreign medicines, but are forming their own high-tech industry. Co-organizer: National Veterinary Association
The annual presentation of projects of the GXP-Profi 2025 International Competition also took place. The participants of the event listened to the speeches of leading experts in the field of quality, who have already implemented innovative solutions at their enterprises and are ready to share real results. The moderator was Irina Spichak, Doctor of Pharmacy, Professor and Executive Director of the Eurasian Academy of Good Practices.
Shortlist of the finalists of the competition and the topics of the submitted projects:
// Akrikhin – Digital GMP Management Archive
// Avexima – Raw material manufacturers and auditors: standardization and digitalization of processes
// Binnopharm Group – A new era of clarity. Optimize GxP documentation based on data ergonomics, typography, and UX design principles
// Biocad – Colony Sampling Robot
// Minskintercaps (Belarus) – A Modern Approach to Assessing Out-of-Trend Results(OOT)
// Polysan – Digital Validation Transformation with AI Assistant - New International Quality Standard Validation 4.0
// Rapharma – Virtual Technologies as a Tool for Improving the Skills of Pharmaceutical Employees
// R-Pharm – An Innovative Approach to the Study of Extractables and Leachables
// Polysan – Computerized Vision-Based System for Incoming Inspection of Printed Packaging Materials Using Artificial Intelligence
// Sotex – Automation of Recording Records with ALCOA+ Compliance Assurance
// Tula Pharmaceutical Factory – Formula Instead of Code: Designing Validated Tables
// Sotex – Validation of the Retention Capacity of Sterilizing Filters Used in the Production of Sterile Drug Products Organizer: Eurasian Academy of Good Practices
 |  |
On the first day of the exhibition, an Information Session was held: "Quality, Import Substitution and Pharma-2030: New Horizons for the Activities of the NCSR". The session was opened by the speech of the Director for Production and Certification of the NCSR Vladimir Gegechkori. He spoke about the implementation of the Pharma-2030 strategy based on the experience of the NCSR: 70% share of localized JI in the market, which is planned to be achieved by 2030; X2 number of applications for domestic GSO for the first half of 2025 (compared to 2024); 258 items of GSO have been launched by NCSO LLC in 5 years. Elena Tereshchuk, Head of Procurement and Sales at the NCSO, presented to the audience the results of localization of the production of consumables for chromatography. Dmitry Chepilo, Head of the Testing Laboratory, noted the expansion of the range of tests carried out by the NCSO. Thus, the expert stressed that a quality management system was introduced in accordance with GOST R ISO 9001-2015, and a GMP certificate was obtained, which gives the right to carry out output quality control. Anton Pershin, Ph.D., General Director of Airlife LLC, made a presentation to the delegates on the advantages of air disinfection technology. Organizer: National Center for Reference Materials
On the second day of the exhibition, a round table "Biologically Active Additives (BAA): Analytics, Regulation and Culture of Consumption" was held. The moderators were Victoria Presnyakova, Head of the Alliance of Pharmaceutical Associations, Director, SRO Association of Independent Pharmacies, and Alexander Zhestkov, Executive Director of the SRO Union of Manufacturers of Dietary Supplements for Food. Nikolay Demidov, CEO of AlfaRM, called pharmacies the largest and "right" channel for the sale of dietary supplements. The expert noted that in each week of 2025, dietary supplements were sold more than in the same period in 2024 - due to inflation and a shift in demand in favor of more expensive medicines. This shift is due to a decrease in the share of the cheapest "corridor" (goods costing less than 100 rubles), this is also due to the rise in price of ingredients, packaging and logistics. The expert also pointed to the growth trend of online sales: sales through the websites and mobile applications of pharmacy chains are growing 2 times faster than offline sales. Alexander Chernichenko, General Director of Muse Media LLC, named such market growth drivers as changing dosages and the possibility of prescribing dietary supplements by doctors. Karina Bulanova, General Director of Zhiznevek LLC, spoke about the problem of counterfeit dietary supplements on marketplaces and raised the issue of legal protection. Lyubov Andreeva, Head of the Dietary Supplements Department of the CRPT, noted that 3 times more manufacturers were registered in the system than expected. As a result, the illegal turnover of dietary supplements decreased from 21% to 5% in 2024-2025. Such a permissive regime reduced the sales of counterfeit by 30 times, and counterfeit sales by 5 times. Tatyana Larina, attorney at law, partner at FirmOne law firm, spoke about the main legislative changes in the field of dietary supplements in 2024-2025:
// Last year, changes were made in the circulation of dietary supplements - now doctors have the right to prescribe dietary supplements if there are indications;
// The government has the right to establish criteria for the quality and effectiveness of dietary supplements;
// The Ministry of Health establishes the procedure for prescribing, listing indications and schemes;
// Pre-trial blocking of Internet resources that sell dietary supplements that do not meet the requirements of the law is possible;
// In addition to Rospotrebnadzor, the Ministry of Health and Roszdravnadzor were among the regulators. Co-organizers: SRO Association of Independent Pharmacies, SRO SP BAD, HUB INFOCONSULT
 |  |
For the first time, the round table "Skincare Cosmetics Market: Analytics, Regulation, Trends and Growth Drivers" was held. The moderators were Victoria Presnyakova, Head of the Alliance of Pharmaceutical Associations, Director of the SRO Association of Independent Pharmacies, and Alexey Donskikh, Director of Pharma and Dietary Supplements at the Skolkovo Foundation. According to Valeria Podgurskaya, a specialist in the Department for the Development of Organic and Green Products of Roskachestvo, an inspection of marketplaces showed that more than 32% of manufacturers make eco-statements for packaging, of which 42% have signs of greenwashing. Ivan Gazin, Project Manager of the Perfumery and Cosmetic Products and Household Chemicals product group of the CRPT, gave a detailed overview of the work carried out and planned to improve the system: a new attribute shelf life / service life was added, multi-product sets were added, and the "pet cosmetics" label was added. The main violations that manufacturers should pay attention to: incorrect code status, the marking code is not read, the marking code is absent on the product, information on the shelf life / service life differs. Yulia Nechaeva, Director of the Strategic Research Department of DSM Group, announced the following data: by 2024, there were 1.6 thousand manufacturers and 40 thousand SKUs; cosmetics account for 2.8% of pharmacy sales and 13.9% of parapharmaceuticals; The capacity of the pharmacy cosmetics market has increased by 11.4% over 10 months. Partner: SRO "Association of Independent Pharmacies"
In continuation of the topic of dietary supplements, a master class was held: "A new era of dietary supplements 2.0 - from clinical guidelines to site inspections". Alexander Solodovnikov, Director of Quality Management at Statendox LLC, said that a Rospotrebnadzor project is being prepared, which will determine the criteria for banning dietary supplements:
// Lack of state registration;
// Presence of prohibited substances in the composition;
// Exceeding the standardized quantities of substances;
// Lack of reliable information about the manufacturer;
// Sale under the guise of food additives.
According to the expert, now, in order to avoid violations, marketplaces have begun to integrate with GIS and MT Honest Mark. In 2024-2025, major seizures and blocking began: Chestny Znak blocked 5.5 million packages of dietary supplements, prevented 12.3 million attempts to sell counterfeit products. In addition, Roskachestvo's monitoring in 2024 revealed large-scale violations on marketplaces: 400+ databases with prohibited substances, more than 80 thousand cards with violations, more than 60 thousand goods without a certificate of state registration. Organizer: Statandox LLC
Traditionally, the Pharmtechprom Forum was held at the exhibition, which included the session "Raw Materials and Materials for Pharmaceutical Production", moderated by Nadezhda Romanova, Sales and Technical Support Manager of HARKE RUS LLC. Yulia Nechaeva, Director of the Strategic Research Department of DSM Group, noted that more than 2.3 thousand wholesale organizations are registered in the MDPL system, while the ratings of participants in the pharmacy segment and the public procurement sector differ significantly. The results of 2025 show that the volume of public procurement is growing faster than the commercial market. A significant contribution to the dynamics is provided by hospital purchases under federal programs, as well as an increase in volumes under the federal benefit: under the WNV program, for example, in ten months of 2025, 10% more was purchased than in the same period in 2024. Growth is also observed in the regional benefit. The state segment is still dominated by foreign manufacturers, although Russian companies also occupy a significant share, the speaker noted. As Yulia Nechaeva noted, the concentration of pharmacy chains is growing: the largest 20 players manage a significant part of the market. In the first ten months of 2025, the pharmacy market grew by 13%, and in October, the growth was provided exclusively by prescription drugs. The main driver remains price factors associated with inflation, the expert stressed. Maxim Pavlenko, Application Specialist at Genetimes ExCell Technology, Inc (ExCellBio), spoke about advanced solutions in the field of cell, gene therapy and biopharmaceuticals for modern medicine. Fengbin Jia, Senior Director of Research, Development and Applications of Shanghai Biotechnology Company OPM Co., shared information about the new generation of high-efficiency culture media, promoting biopharmaceutical production, and improving product quality. Anastasia Pantyukhina, Commercial Director of Vitek LLC, touched upon such an important topic as high-performance polymers for coating tablets, masking taste and accelerating disintegration in solid dosage forms. The session was concluded by Yuri Kuznetsov, General Director of Arsenal Athlete LLC, with his report on the AI-controlled capsule for pharma and dietary supplements as a single quality circuit: chain stability, production predictability and opportunities for private labels. Partner: Genetimes ExCell Technology
 |  |
The Pharmtechprom forum also hosted the session "Packaging Materials and Equipment for Pharmaceutical Production". During the event, its moderator, Evgeny Slinyakov, General Director of PROMIS JSC, presented an overview of the current situation in the pharmaceutical packaging market and shared forecasts for the coming years. According to the speaker, the dynamics of sales in the pharmaceutical market shows multidirectional trends: every year the number of packages sold decreases, while the volume of sales in rubles is growing, largely due to inflation and currency fluctuations. At the same time, production facilities allow us to produce more products than the market is able to consume. During 2025, the sales volume by month remains stable - about 450 million packages. According to the speaker, domestic medicines account for 66% of the sales structure in 2025. Mikhail Toreev, Head of Packaging Equipment Sales at Ulma Packaging LLC, shared his opinion on modern packaging solutions for pharmaceutical production. Konstantin Tkachenko, Head of Packaging Equipment InterPharmTehcnology, spoke about effective solutions for individual and group packaging of finished medicinal products, its aggregation and serialization. Ruslan Chuev, General Director of Fencer TT LLC (part of the NEOPOLIS Group of Companies), highlighted the current tasks of the Russian flexible packaging market for the pharmaceutical industry. Grigory Cherchenko, General Director of Sofrinsky Packaging Manufactories LLC, spoke about the different types of vials for medicines produced by the company and their advantages. Partner: InterPharmTehcnology
On the second day of the exhibition, the session "Training of Personnel for the Pharmaceutical Engineering Industry: New Challenges and Solutions" was held. The discussion was moderated by Oleg Malakhov, Chairman of the Board of Directors of the Prime Group of Companies, member of the General Council of Business Russia, who noted that mentoring systems have proven themselves well, and the creation of pharmaceutical production requires a wide range of competencies. Hussein Pliev, General Director of SMART Engineers Group of Companies, Vice President of the NOTECH Association, said that since 2024, the Association has been working on a system of advanced training and developing opportunities for internships for students at enterprises. This area is combined into the Personnel Competence Center. In addition, a special course for managers, based on practical experience, was created, and interaction with the NAVIBRIS engineering knowledge platform was established. Alexander Moldavsky, Managing Partner of Almoldy Partner, former head of Abbott in Russia, noted that pharmaceutical companies are actively using international experience in personnel training. The speaker noted that universities sent all students to them for internships, and the company left the best of them to work. Olga Arshanskaya, Development Director of IRBIS Engineering Corporation, noted that in recent years there has been a "boom" in the pharmaceutical industry, and the shortage of qualified personnel is increasing, both in construction and in pharmaceuticals. There are few specialists on the market, but at the same time, there are also not enough high-quality vacancies, which is aggravated by the period of demographic hole. The expert said that an open professional trajectory is being formed within her corporation: there is a program "Young Specialist", "Honored Employee" and the IRBIS Corporate Academy. Artem Malakhov, Chief Operating Officer of Primekey Group, stressed that his company conducts training courses for students of construction universities, organizes an annual competition and opened a construction class for high school students. Organizer: Primekey Group
On the third day, a plenary session was held as part of the Pharmtech & Ingredients business program, which was divided into two parts. Part 1. Traceability of the origin of APIs. From experiment to everyday practice in the EAEU space. The session was moderated by Vladislav Shestakov, Director of the FSI "SID and NP of the Ministry of Industry and Trade of the Russian Federation". Philip Romanov, General Director of the Association of Participants in the Circulation of Medicines and Medical Products "LEKMEDOBRASCHENIE", raised the issue of a new list of strategically important medicines (SPLP). Egor Zhavoronkov, Head of the Department for Work with Socially Significant Goods of the CRPT, spoke about the technical side of the traceability system. He noted that by 2025 the system is ready, but it is expected to add an audit of current balances and correct declaration, and in 2026 the system will be technically adapted to the non-linear processes of manufacturers. Lyudmila Shcherbakova, President of Bright Way Group, reminded the participants of the importance of balancing control so that it does not become excessive, and trust. She also raised the issue of creating an intermediate market. Sergey Avdeenko, Head of the Government Relations Department of Promomed Group, spoke about the experiment of traceability and the company's participation in it. Maria Borzova, Legal Advisor to the Association of Pharmaceutical Manufacturers of the EAEU, answered questions about the readiness of enterprises to implement a traceability system, about the risks and difficulties in the transition to the 2026 model and noted that everything is going on as usual, but there is still a long way to go. According to Evgenia Shapiro, General Director of PSK Pharma, regarding the readiness of the transition to a traceability system, "we can achieve the most ambitious goals", but it is important to assess the stage at which we are – a lot of work has already been done, but there are still some conceptual issues that need to be worked out.
 |  |
Part 2. "The second odd man": criteria, rules, preferences. Moderator Alexey Shvyndenkov, Senior Partner of the Marillion Group of Companies, brought the audience up to date: from January 1, 2025, the "second odd man" rule, according to which an application for an imported product is automatically rejected if an application for a similar domestic product is submitted to an auction, is valid for the list of vital and essential drugs, and from 2026 it will begin to operate with clarifications for SZLS, which affects the interests of both businesses, and patients. Olga Kravtsova, Deputy Director of the Department for the Development of the Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of the Russian Federation, spoke about the general concept of the "second odd man" and shared her expectations about the planned operation of the mechanism. The goal is to implement the traceability of the production of medicines on a full cycle so that the companies are truly Russian at state auctions. Alexander Bykov, Director for Healthcare Economics at R-Pharm, expressed the opinion that it makes sense to provide for the possibility of a test mode of the rules until March 1, 2026, in order to, among other things, work out the Decree of the Government of the Russian Federation No719, which provides for a point assessment of the degree of localization of industrial products. Dmitry Nakhamchen, Director for Government Relations and Market Access at Geropharm LLC, expressed the opinion that the implementation of initiatives should not be postponed, because such a shift can be perceived in two ways: by both investors and manufacturers, for whom this stage will be the quintessence of 15 years of measures to support Russian producers. The expert also noted that dividing the list of SLAs is a good solution that will remove the differences between the parties. Yuri Zhulyov, Co-Chairman of the All-Russian Union of Patients, spoke about the expectations and risks for the patient community from the future introduction of a more stringent mechanism. Dmitry Zaitsev, General Director of Pharmstandard JSC, spoke in more detail about the implementation of the "odd man out" rule and noted that manufacturers of Russian drugs have moved to this system smoothly, over 15 years through the Pharma-2020 program. Partner of the plenary session: GxPnews
On the third day of the exhibition, the session "Technologies, Equipment, Related Processes and Products for Pharmaceutical Production" was also held at the Pharmtechprom Forum. The moderator was Natalia Piatigorskaya, Doctor of Linguistics, Professor, Head of the Department of Industrial Pharmacy, Deputy Director for Research of the Institute of Translational Medicine and Biotechnology of the I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. In the first part of the session, Anna Yakhutina, Head of the Bioequipment Sales Group of Tofflon Rus LLC, and Artem Demidenko, Ph.D., Leading Scientific Expert of Tofflon RUS LLC, spoke about future ways of commercialization of biopharmaceuticals and new generation vaccines. Oleg Demin, Head of SMA Representative Office in the CIS SHANDONG SMA PHARMATECH CO., LTD, presented a report on technologies and solutions for continuous production of solid dosage forms. Elena Mozhayskaya, Head of Key Account Department, TK ELEMENT LLC, and Natalia Novozhilova, Partner of Element, Ph.D., Commercial Director of Sevko&Co, presented HPLC Skorokhod, and Vishal Vagh, Sales and Marketing Director of ADAM FABRIWERK PVT LTD, presented Super-skids for the production of sterile injectable forms of medicines. Maria Troyan, Deputy Director for Scientific and Technical Work of Labconcept Group, devoted her speech to the use of LicArt chromatographs at various stages of pharmaceutical production. Partner: Tofflon
In the second part of the session, Boris Zaichik, Ph.D., Head of the Research Center of AquaChrome LLC, presented the line of mass spectrometers of the Waters company and spoke about the technical characteristics of the Synart XS high-resolution mass spectrometer. Alexandra Popova, Ph.D., Head of the Laboratory of Liquid Chromatography, Associate Professor at Lomonosov Moscow State University, representative of LLC TD HIMMED, spoke about ChemMed's own HPLC columns for laboratories of pharmaceutical enterprises. The moderator of the second part of the session was Oleg Spitsky, Head of Quality System, GMP Expert, Biopharmproekt LLC; Member of the Board of Directors of ISPE Eurasia.
On the third day of the exhibition, a practical seminar was also held: Pharmaceutical business with China: how to create a joint venture, protect intellectual property and manage payments. Anastasia Valova, Managing Partner of Sinoruss Consulting, spoke at the seminar. The speaker notes that China is the largest producer of substances, bioengineering, biotechnological solutions and finished dosage forms. However, the market is more strictly regulated than the Russian one, and differs significantly in the logic of work. The distinctive features of the Chinese market are the building of long-term relationships, the role of provinces, strict regulation and control of technology transfer.
Interview point. For the first time this year, "Interview Point" was launched - a series of interviews with participants and industry experts - representatives of industry ministries and departments, associations, manufacturers of medicines and participants of the exhibition. We learned the opinions and forecasts of market participants, analyzed key problems and challenges, discussed opportunities and prospects for the development of the industry. Together with the GxPnews portal and its editor-in-chief Veronika Kulakova, a series of interviews was conducted, where they talked about the topic "Pharma-2030: a look from the inside".
 |  |
Among the speakers:
// Vladislav Shestakov, Director, SID and GP of the Ministry of Industry and Trade of the Russian Federation
// Alexander Bykov, Director for Health Economics, R-Pharm
// Evgenia Shapiro, General Director, PSK Pharma
// Dmitry Nakhamchen, Director for Government Relations and Market Access, Geropharm
// Irina Vendilo, General Director, Roskhimreaktiv Association
// Vladimir Gegechkori, Director of Production and Certification of Production and Certification, NCSR
// Irina Spichak, Doctor of Pharmacy, Professor, Executive Director, Eurasian Academy of Good Practices
// Grigory Cherchenko, General Director, Sofrinsky Packaging Manufactories
// Vladimir Smirnov, General Director, Mediana-Filter
The partner of the business program of the exhibition was Statandox LLC. The partners of the Pharmtechprom Forum sessions were Tofflon, InterPharmTechnology, and ExCell.
In 2025, Pharmtech & Ingredients was held with the official support of the Ministry of Industry and Trade of the Russian Federation, the Association of Russian Pharmaceutical Manufacturers, the Union of Professional Pharmaceutical Organizations, the Association of Pharmaceutical Manufacturers of the Eurasian Economic Union, and the Association of Independent Pharmacies.
// GxP News – General Media Partner
The exhibition was held with the information support of: the newspaper "Pharmaceutical Bulletin", the Information and Analytical Journal "CHEMICAL EXPERT", the Journal "Pharmaceutical Technologies and Packaging", the National Pharmaceutical Journal, the information portal "Development and Registration of Medicines", "Kazakhstan Pharmaceutical Bulletin", "Pharmaceutical Review of Kazakhstan", the journal "Laboratory and Production", the federal magazine "Business Russia", the information portal " INPHARM", "Pharma RF", "Healthcare of Russia", the industry portal "PHARMPROM", the portal "Remedium", the publishing house "August Borg", the portal "Ruhim.ru", the portal/magazine "SpaceHealth Space", the portal "Cosmetology-info.ru", "Moscow Pharmacies", "AptekaMos", etc.
